306 related articles for article (PubMed ID: 21347319)
1. Investigating the potential role of genetic and epigenetic variation of DNA methyltransferase genes in hyperplastic polyposis syndrome.
Drini M; Wong NC; Scott HS; Craig JM; Dobrovic A; Hewitt CA; Dow C; Young JP; Jenkins MA; Saffery R; Macrae FA
PLoS One; 2011 Feb; 6(2):e16831. PubMed ID: 21347319
[TBL] [Abstract][Full Text] [Related]
2. BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status.
Yang S; Farraye FA; Mack C; Posnik O; O'Brien MJ
Am J Surg Pathol; 2004 Nov; 28(11):1452-9. PubMed ID: 15489648
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
[TBL] [Abstract][Full Text] [Related]
4. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.
Kambara T; Simms LA; Whitehall VL; Spring KJ; Wynter CV; Walsh MD; Barker MA; Arnold S; McGivern A; Matsubara N; Tanaka N; Higuchi T; Young J; Jass JR; Leggett BA
Gut; 2004 Aug; 53(8):1137-44. PubMed ID: 15247181
[TBL] [Abstract][Full Text] [Related]
5. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
[TBL] [Abstract][Full Text] [Related]
6. A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome.
Boparai KS; Dekker E; Polak MM; Musler AR; van Eeden S; van Noesel CJ
Am J Pathol; 2011 Jun; 178(6):2700-7. PubMed ID: 21641392
[TBL] [Abstract][Full Text] [Related]
7. Concordant CpG island methylation in hyperplastic polyposis.
Chan AO; Issa JP; Morris JS; Hamilton SR; Rashid A
Am J Pathol; 2002 Feb; 160(2):529-36. PubMed ID: 11839573
[TBL] [Abstract][Full Text] [Related]
8. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
[TBL] [Abstract][Full Text] [Related]
9. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
10. Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype.
O'Brien MJ; Yang S; Clebanoff JL; Mulcahy E; Farraye FA; Amorosino M; Swan N
Am J Surg Pathol; 2004 Apr; 28(4):423-34. PubMed ID: 15087661
[TBL] [Abstract][Full Text] [Related]
11. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
12. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
13. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.
O'Brien MJ; Yang S; Mack C; Xu H; Huang CS; Mulcahy E; Amorosino M; Farraye FA
Am J Surg Pathol; 2006 Dec; 30(12):1491-501. PubMed ID: 17122504
[TBL] [Abstract][Full Text] [Related]
14. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.
Nosho K; Shima K; Irahara N; Kure S; Baba Y; Kirkner GJ; Chen L; Gokhale S; Hazra A; Spiegelman D; Giovannucci EL; Jaenisch R; Fuchs CS; Ogino S
Clin Cancer Res; 2009 Jun; 15(11):3663-71. PubMed ID: 19470733
[TBL] [Abstract][Full Text] [Related]
15. Serrated lesions of the appendix in serrated polyposis patients.
Bettington M; Brown IS; Rosty C
Pathology; 2016 Jan; 48(1):30-4. PubMed ID: 27020206
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutations in aberrant crypt foci and hyperplastic polyposis.
Beach R; Chan AO; Wu TT; White JA; Morris JS; Lunagomez S; Broaddus RR; Issa JP; Hamilton SR; Rashid A
Am J Pathol; 2005 Apr; 166(4):1069-75. PubMed ID: 15793287
[TBL] [Abstract][Full Text] [Related]
17. Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps.
Kim YH; Kakar S; Cun L; Deng G; Kim YS
Int J Cancer; 2008 Dec; 123(11):2587-93. PubMed ID: 18798261
[TBL] [Abstract][Full Text] [Related]
18. Molecular classification and genetic pathways in hyperplastic polyposis syndrome.
Carvajal-Carmona LG; Howarth KM; Lockett M; Polanco-Echeverry GM; Volikos E; Gorman M; Barclay E; Martin L; Jones AM; Saunders B; Guenther T; Donaldson A; Paterson J; Frayling I; Novelli MR; Phillips R; Thomas HJ; Silver A; Atkin W; Tomlinson IP
J Pathol; 2007 Aug; 212(4):378-85. PubMed ID: 17503413
[TBL] [Abstract][Full Text] [Related]
19. [Immunophenotypes and gene mutations in colorectal precancerous lesions and adenocarcinoma].
Huang WT; Qiu T; Ling Y; Shi SS; Guo L; Zheng B; Lü N; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2013 Oct; 42(10):655-9. PubMed ID: 24433726
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
